Geron Revenue Growth Rates (GERN), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Geron Corporation  (NASDAQ: GERN)
 

GERN's Revenue Growth by Quarter and Year

Geron's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/GERN/growth
https://api.csimarket.com/api/v1/companies/GERN/fundamentals
https://api.csimarket.com/api/v1/companies/GERN/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
GERN Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 60.19
2nd Quarter June 57.48
1st Quarter March 51.84
FY 169.51

GERNs Annual Revenue
Geron's Revenue in the fiscal year 2025 $ 183.62 millions
Geron's Revenue in the fiscal year 2024 $ 76.50 millions
Geron's Revenue in the fiscal year 2023 $ 0.24 millions
Geron's Revenue in the fiscal year 2022 $ 0.60 millions
Geron's Revenue in the fiscal year 2021 $ 1.39 millions




GERN Revenue third quarter 2026 Y/Y Growth Comment
Geron Corporation reported Revenue improvement of 27.44% year on year in the third quarter 2026, to $ 60.19 millions, this is lower than Geron Corporation's recent average Revenue surge of 4468.04%.

Looking into third quarter 2026 results within Major Pharmaceutical Preparations industry 88 other companies have achieved higher Revenue growth. While Geron Corporation' s Revenue rise of 27.44% ranks overall at the positon no. 1166 in the third quarter 2026.


GERN Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 27.44 %
2nd Quarter June 17.21 %
1st Quarter March 30.91 %
FY   -

Financial Statements
Geron's third quarter 2026 Revenue $ 60.19 millions GERN's Income Statement
Geron's third quarter 2025 Revenue $ 47.23 millions Quarterly GERN's Income Statement


GERN Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 4.71 %
2nd Quarter June 10.88 %
1st Quarter March 8.54 %
FY (Year on Year)   -


Back to GERN Growth rate Comparisons >> Back to GERN Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #89
Healthcare Sector #219
Overall #1166

Revenue Y/Y Growth Statistics
High Average Low
204413.04 % 4468.04 % -96.81 %
(Dec 31 2024)   (Mar 31 2018)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #89
Healthcare Sector #219
Overall #1166
Revenue Y/Y Growth Statistics
High Average Low
204413.04 % 4468.04 % -96.81 %
(Dec 31 2024)   (Mar 31 2018)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Geron's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
13988.84 % 376.58 % -99.38 %
(Sep 30 2015)  


GERN's III. Quarter Q/Q Revenue Comment
Geron Corporation achieved in the III. Quarter 2026 below company average Revenue growth of 4.71% quarter on quarter, to $ 60.19 millions.

Although the III. Quarter 2026 Revenue Q/Q growth was lower than the regular , this has been yet encouraging story, as the III. Quarter surge, eclipses the -3.69% growth in the III. Quarter a year ago

Within Major Pharmaceutical Preparations industry 72 other companies have achieved higher Revenue quarter on quarter growth. While Geron's Revenue growth quarter on quarter, overall rank is 1193.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #73
Healthcare Sector #176
Overall #1193
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #73
Healthcare Sector #176
Overall #1193
Revenue Q/Q Growth Statistics
High Average Low
13988.84 % 376.58 % -99.38 %
(Sep 30 2015)  


GERN's III. Quarter Q/Q Revenue Comment
Geron Corporation achieved in the III. Quarter 2026 below company average Revenue growth of 4.71% quarter on quarter, to $ 60.19 millions.

III. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the -3.69% in the III. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 72 other companies have achieved higher Revenue quarter on quarter growth. While Geron's Revenue growth quarter on quarter, overall rank is 1193.


Geron's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025) 12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 204.30
Y / Y Revenue Growth (TTM) 24.61 %
Year on Year Revenue Growth Overall Ranking # 5
Seqeuential Revenue Change (TTM) 4.31 %
Seq. Revenue Growth (TTM) Overall Ranking # 404


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Geron's cumulative twelve months Revenue were $ 204 millions, company would post below average annual Revenue growth of 4.31% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Geron's Revenue growth from the 57.48% growth in Mar 31 2026.

Among companies within the Healthcare sector 2 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 4 to 5.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 54
Healthcare Sector # 3
Overall # 5

Revenue TTM Y/Y Growth Statistics
High Average Low
32176.37 %
 1545.91 %
-85.78 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 54
Sector # 102
S&P 500 # 404
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Geron's cumulative twelve months Revenue were $ 204 millions, company would post below average annual Revenue growth of -85.78% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Geron's Revenue growth from the 57.48% growth in Mar 31 2026.

Among companies within the Healthcare sector 2 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 4 to 5.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 54
Healthcare Sector # 3
Overall # 5

Revenue TTM Y/Y Growth Statistics
High Average Low
32176.37 %
1545.91 %
-85.78 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 54
Sector # 102
S&P 500 # 404




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
GERN's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue growth for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Billiontoone Inc 47.43%$ 47.431 millions
Arcutis Biotherapeutics Inc 45.05%$ 45.052 millions
Zevra Therapeutics Inc 44.86%$ 44.864 millions
Xeris Biopharma Holdings Inc 44.16%$ 44.158 millions
Nephros Inc 43.60%$ 43.602 millions
Cardiff Oncology Inc 42.50%$ 42.500 millions
Neurocrine Biosciences Inc 41.24%$ 41.238 millions
Transmedics Group Inc 41.15%$ 41.149 millions
Uniqure N v 40.39%$ 40.394 millions
Harrow Inc 40.00%$ 40.001 millions
Mirum Pharmaceuticals Inc 39.63%$ 39.629 millions
Caredx Inc 39.29%$ 39.285 millions
Halozyme Therapeutics Inc 39.15%$ 39.154 millions
Eli Lilly And Company38.61%$ 38.613 millions
Myomo Inc 37.42%$ 37.416 millions
Editas Medicine Inc 37.41%$ 37.412 millions
Beyond Air Inc 36.55%$ 36.545 millions
Clearpoint Neuro Inc 36.27%$ 36.271 millions
Regeneron Pharmaceuticals Inc 36.27%$ 36.265 millions
Travere Therapeutics Inc 36.22%$ 36.215 millions
Omada Health Inc 36.13%$ 36.133 millions
Guardant Health Inc 36.12%$ 36.116 millions
Natera Inc 34.08%$ 34.077 millions
Establishment Labs Holdings Inc 34.08%$ 34.075 millions
Beone Medicines Ltd 33.86%$ 33.861 millions
Ceribell Inc 33.72%$ 33.721 millions
Zomedica Corp 33.12%$ 33.123 millions
Intuitive Surgical Inc 32.71%$ 32.714 millions
Adc Therapeutics Sa32.20%$ 32.197 millions
Biomarin Pharmaceutical Inc32.02%$ 32.019 millions


About Geron Revenue Growth Rates (GERN), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Geron Corp (CIK 886744).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0000886744-26-000041
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Geron Corp’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.